Table 2 – Comparison of treatment paradigms for BP loweringa
Treatment paradigm for BP lowering | Population treated % (95% CI) | CVD events averted over 10 years due to treatment n (95% CI) | Estimated percentage reduction of CVD events averted over 10 years compared to no treatment† % (95% CI) | Percentage change in number treated compared to current practice % (95% CI) | Percentage change in number of events averted over 10 years compared to current practice % (95% CI) | Percentage change in number treated compared to “hypertension” paradigm % (95% CI) | Percentage change in number of events averted over 10 years compared to “hypertension” paradigm % (95% CI) |
|---|---|---|---|---|---|---|---|
Current practice | 19·6 (18·4–20·9) | 502 (471–533) | 5·3 (5·1–5·5) | – | – | – | – |
Treatment of “hypertension” (BP > 140/90 mmHg) | 32·6 (30·8–34·5) | 869 (820–919) | 9·2 (9·0–9·5) | + 66·2 (65·8–66·5) | + 74·2 (72·5–76·0) | – | – |
Treatment according to NPCDCS guidelines | 21·0 (19·9–22·2) | 886 (838–934) | 9·4 (9·1–9·7) | + 7·2 (6·9–7·4) | + 77·3 (75·6–79·0) | −35.5 (−35.2--35.8) | + 1.7 (1.4–2.2) |
Treatment of all at intermediate and high risk | 23·2 (22·0–24·3) | 936 (889–983) | 9·9 (9·7–10·2) | + 17·9 (17·6–18·2) | + 87·2 (85·8–88·5) | −29.1 (−28.8--29.3) | + 7.4 (6.7–8·3) |
Treatment of all at high risk | 17·9 (16·9–18·8) | 812 (768–856) | 8·6 (8·4–8·9) | −9·0 (−8·8--9·2) | + 62·7 (60·7–64·6) | −45.2 (−44.9--45.5) | −6.6 (−5.9--7.4) |
Treatment of all above 45 years of age | 76·5 (75·4–77·6) | 1233 (1216–1250) | 13·0 (12·7–13·3) | + 289·5 (289.2–289.8) | + 145·7 (144.6–146.8) | + 134.4 (133.7–135.6) | + 41.0 (37.1–45.9) |
Treatment of all above 55 years of age | 44·5 (43·2, 45·8) | 909 (883–935) | 9·6 (9·3–9·9) | + 126·6 (126.3–126.9) | + 80·7 (78.9–82.4) | + 36.4 (36.1–36.7) | + 3.7 (3.2–4.3) |